For patients with < @ years since their first symptom , significantly fewer new/newly enlarged T@ lesions were observed with fingolimod versus IFN-@a IM ( mean number , @ vs. @ ; P = @ ) or placebo ( @ vs. @ ; P < @ ) ; the mean number of gadolinium-enhancing T@ lesions was significantly reduced versus placebo ( @ vs. @ ; P < @ ) .